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The antimalarial activity of heparin, against which there are no resistances known, has not been 
therapeutically exploited due to its potent anticoagulating activity. Here, we have explored the 
antiplasmodial capacity of heparin-like sulfated polysaccharides from the sea cucumbers Ludwigothurea 
grisea and Isostichopus badionotus, from the red alga Botryocladia occidentalis, and from the marine 
sponge Desmapsamma anchorata. In vitro experiments demonstrated for most compounds significant 
inhibition of Plasmodium falciparum growth at low-anticoagulant concentrations. This activity was 
found to operate through inhibition of erythrocyte invasion by Plasmodium, likely mediated by a 
coating of the parasite similar to that observed for heparin. In vivo four-day suppressive tests showed 
that several of the sulfated polysaccharides improved the survival of Plasmodium yoelii-infected mice. 
In one animal treated with I. badionotus fucan parasitemia was reduced from 10.4% to undetectable 
levels, and Western blot analysis revealed the presence of antibodies against P. yoelii antigens in its 
plasma. The retarded invasion mediated by sulfated polysaccharides, and the ensuing prolonged 
exposure of Plasmodium to the immune system, can be explored for the design of new therapeutic 
approaches against malaria where heparin-related polysaccharides of low anticoagulating activity could 
play a dual role as drugs and as potentiators of immune responses.
Among the infectious diseases, malaria ranks probably first in the perversity of its causal agent, the protist 
Plasmodium spp. This parasite distributes its life cycle1 between two hosts, humans and the females of certain 
species of mosquitoes from the genus Anopheles. Following a mosquito bite, in a matter of minutes sporozoites 
enter hepatocytes, where they will develop and replicate into thousands of merozoites that are released into the 
blood circulation to invade red blood cells (RBCs). Because RBCs are unable to process and present antigens, 
early intraerythrocytic ring stages remain invisible to the immune system until the late stages trophozoites and 
schizonts develop and significantly modify the parasitized RBC (pRBC) plasma membrane to meet their needs 
for membrane transport processes2. Even then, the proteins exported to the pRBC plasma membrane have a very 
high antigenic variation3 which leads to waves of parasitemia and persistent infections despite antibody-mediated 
immune pressure. Erythrocytes infected with mature stages of the malaria parasite bind to endothelial cells in 
the capillaries of tissues in a phenomenon known as sequestration, which allows Plasmodium to replicate while 
evading splenic clearance1. pRBCs can also adhere to non-infected RBCs giving rise to rosettes4, and they can 
form clumps through platelet-mediated binding to other pRBCs. These events, which may lead to occlusion of the 
microvasculature, are thought to play a major role in the fatal outcome of severe malaria. Because the blood-stage 
infection is responsible for all symptoms and pathologies of the disease, pRBCs have traditionally been a main 
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chemotherapeutic target5. However, the fast evolution of Plasmodium resistance against virtually every new drug 
being deployed6, calls for urgent efforts in the research and development of new antimalarial therapeutic agents.
Negatively charged polysaccharides, such as heparin, chondroitin and dextran sulfates, fucoidan, and the 
nonsulfated glycosaminoglycan (GAG) hyaluronan, block cytoadhesion of pRBCs to various host receptors7–10 
and disrupt P. falciparum rosettes11,12. Heparin and related sulfated polysaccharides possess antimalarial activ-
ity that has been described to operate through inhibition of RBC invasion by merozoites9,13–16. Remarkably, 
efforts to select for heparin-resistant parasites have proven unsuccessful16, which places sulfated polysaccha-
rides as interesting candidates in the race for finding efficient long-lasting antimalarials. Proteomic analysis 
has revealed that heparin interacts with multiple apical surface proteins in P. falciparum merozoites17,18, likely 
blocking their association with the erythrocyte membrane after initial attachment. Naturally acquired immu-
nity to malaria is largely directed against extracellular merozoites19, but currently there are no drugs targeting 
erythrocyte invasion by Plasmodium20, although some candidates have been proposed21. The potential use of 
heparin as drug in malaria therapy22–26 has been hindered by its high anticoagulation and bleeding properties27 
and by the potential risk of infection since some GAGs are obtained from mammals. As an interesting alterna-
tive, non-mammalian marine organisms are a rich source of unique sulfated polysaccharides, some of them with 
structures resembling pRBC-binding GAGs28–30. The fucosylated chondroitin sulfate (FucCS) from the echino-
derm Ludwigothurea grisea had been shown to have serpin-unrelated anticoagulant properties31,32, which differ 
from the serpin-dependent anticoagulant mechanism of mammalian heparins. Former data reporting dissocia-
tion of the anticoagulant, bleeding, and antithrombotic effects of L. grisea FucCS33, together with recent results 
revealing its inhibition of P. falciparum cytoadhesion and growth14, suggest that marine sulfated glycans might 
offer interesting alternatives to heparin for future antimalarial therapies. To trace correlations between the struc-
ture of these new sulfated polysaccharides and their inhibition of Plasmodium growth, we have examined several 
compounds containing sulfated fucose units in a well-defined repetitive sequence; namely, we have determined 
the antimalarial and anticoagulating activities of FucCSs and sulfated fucans from the sea cucumbers L. grisea29,34 
and Isostichopus badionotus, of a sulfated galactan from the red alga Botryocladia occidentalis, and of a sulfated 
glycan from the marine sponge Desmapsamma anchorata.
Results
Characterization of sulfated polysaccharide size and integrity. I. badionotus FucCS has simple 
branches of sulfated α -fucose (Fig. 1a), composed of a single monosaccharide unit, either disulfated at positions 2 
and 4 (~90%) or exclusively 4-sulfated (~10%)35. L. grisea FucCS has more complex branching structures, mostly 
composed of disaccharide units of α -fucose, non-sulfated and 3-sulfated at the nonreducing and reducing ends, 
respectively. This FucCS also has small amounts of branches composed of single α -fucose units, either 2,4-disul-
fated (~27%) or 2,3-disulfated (~20%)35. The linear sulfated fucans from these echinoderms (Fig. 1b) contain 
repetitive tetrasaccharide sequences, defined by the patterns of sulfation at positions 2 and 436,37, which differ 
exclusively in the sulfation of the second residue of the tetrasaccharide: 2-sulfated in I. badionotus and non-sul-
fated in L. grisea. Unlike the majority of sulfated galactans from red algae, that of B. occidentalis (Fig. 1c) has a 
relatively simple structure, varying only in the sulfation pattern of its units38. The sponge glycan used here (Mr 
~200 kDa) has had its structure only partially elucidated; preliminary gas chromatography/mass spectroscopy 
analysis indicated that it is a heteropolysaccharide composed of glucose (75%), fucose (17%) and galactose (8%), 
with a molar ratio sulfate:total monosaccharide of ~1.5 (data not shown). Integrity of these molecules was ana-
lyzed by polyacrylamide gel electrophoresis (Fig. 2), and the result obtained was found to be consistent with the 
respective approximate molecular masses calculated by size exclusion chromatography after polysaccharide puri-
fication from their natural sources, indicating the absence of significant degradation. The bands observed in 6% 
polyacrylamide gels exhibited a certain degree of size polydispersity, as it is typical of this group of compounds.
Antimalarial and anticoagulating activities in vitro of sulfated polysaccharides. The antimalarial 
activity of the polysaccharides was analyzed in in vitro cultures of P. falciparum (Fig. 3a), revealing for most of 
them a significant inhibition of the parasite’s growth, with IC50s between 2.3 and 20.3 μg/mL (Table 1). These 
activities were similar to those found for different heparin batches (between 4 and 18 μg/mL according to our own 
data)39. The sole exception was the D. anchorata glycan, whose antimalarial activity was found to be relatively low, 
with an IC50 ~66 μg/mL. No correlation was found between Plasmodium growth inhibition and polysaccharide 
size, since the two best activities were for the largest and smallest structures corresponding, respectively, to the B. 
occidentalis galactan (~700 kDa) and the L. grisea FucCS (~30 kDa). The sulfated polysaccharides from marine 
organisms assessed here, especially the fucosylated chondroitin sulfates and sulfated fucans from sea cucum-
bers, have been showing remarkably homogenous structures, as demonstrated by their coincident NMR spectra 
obtained from different preparations29,35,40. Therefore, if these polysaccharides are extracted and purified properly, 
no significant variations in structure, and thus in pharmacological properties, are expected between batches.
According to the activated partial thromboplastin time (APTT) determined in vitro for the sulfated polysac-
charides used in this work (Fig. 3b and Supplementary Table 1), the three best antimalarial compounds (both 
FucCSs and the galactan) were the most anticoagulant and the three polymers more innocuous for Plasmodium 
(both fucans and the sponge glycan) exhibited the worst anticlotting activities. Nevertheless, all compounds had 
comparatively small anticoagulant activities never above 16% of that from heparin, as demonstrated by their 
significantly higher doses necessary to double the control APTT (Supplementary Table 1), which suggests that 
anticoagulating and antimalarial activities are not directly related.
Sulfated polysaccharides inhibit Plasmodium invasion of red blood cells. Since the antimalar-
ial mechanism of heparin and related polysaccharides had been described to operate through inhibition of the 
invasion of RBCs by Plasmodium, we proceeded to investigate the invasion inhibition activity of the marine 
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sulfated polysaccharides. Late-stage pRBC cultures that had been treated with the different structures revealed 
upon microscopic examination at 20 h post-treatment a clear decrease in ring stages relative to untreated samples 
(Fig. 4). Polysaccharide-treated samples thus showed a delay in P. falciparum development, as evidenced by the 
presence at 40 h within the intraerythrocytic cycle of a significant fraction of ring stages relative to untreated con-
trols which contained, as expected, trophozoites and schizonts only. Quantitative microscopic counts evidenced a 
clear decrease in the invasion rate of all polysaccharide-treated samples (Table 2). Maturation rates, on the other 
hand, were not negatively affected, indicating that if rings are formed, their progression towards trophozoites 
and schizonts seems to proceed normally. The observation that some of the samples had maturation rates larger 
than the untreated control suggests that these cases reflected the presence of a significant number of parasites 
that either completed their invasion or started their differentiation into identifiable rings after the count of ring 
stages was made. A clear example of this is represented by L. grisea FucCS-treated samples, whose parasitemias at 
40 h post-treatment were higher than those expected from the low invasion rate reported for this polysaccharide 
in Table 2. Likely, the reduced ring numbers observed in microscopic counts of in vitro assays indicates a slower 
invasion process of otherwise viable merozoites. These retarded invasions (therefore not detected as ring stages) 
eventually develop into trophozoites, which results in an apparently high maturation rate from rings to late forms. 
Indeed, when multiplying invasion by maturation rates, which gives an approximate comparative estimation of 
parasite viability, the values obtained (not shown) are in good agreement with the respective inhibitory effects on 
parasite growth (Fig. 3), with L. grisea FucCS exhibiting the highest antiplasmodial activity when all polysaccha-
rides are tested at 4 μg/mL. Flow cytometry analyses of P. falciparum cultures treated at late stage with sulfated 
polysaccharides confirmed a clear dose-dependent invasion inhibition at their respective IC50 (Fig. 5a) and IC90 
(Fig. 5b).
Figure 1. Chemical structures of the sulfated polysaccharides used in this work. (a) The L. grisea and 
I. badionotus fucosylated chondroitin sulfates share a similar backbone (left) but differ on their sulfated 
fucose branches (right). (b) L. grisea and I. badionotus sulfated fucans have similar tetrasaccharide repeating 
structures but differ exclusively on the sulfation of the second unit. (c) The sulfated galactan from the red alga 
B. occidentalis contains alternating α - and β -galactose units with distinct sulfation patterns. Sulfation sites are 
shadowed.
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The accumulated experimental evidence indicates that invasion inhibition is the antimalarial mechanism 
through which sulfated polysaccharides operate. However, the short time that free merozoites are present in 
the blood circulation suggests that the process of parasite binding might occur, at least in part, inside pRBCs. 
Following previously established protocols39, we added fluorescein-labeled heparin to live pRBC cultures and 
after 30 min of incubation the samples were processed for confocal fluorescence microscopy analysis. The result-
ing data show that heparin added to living pRBC cultures not only specifically targeted pRBCs vs. RBCs in vitro, 
but it entered live pRBCs and bound intraerythrocytic developing merozoites (Supplementary Fig. 1).
In vivo antimalarial activity analysis of sulfated polysaccharides. P. yoelii-infected mice were 
treated iv with polysaccharide doses selected after consideration of their in vitro antimalarial activity, anticoagu-
lation capacity, and unspecific cytotoxicity. Although a significant toxicity in endothelial cell cultures was found 
at some of the administered doses for most marine sulfated polysaccharides when compared to the same heparin 
concentrations (Fig. 6a and Supplementary Table 2), no adverse effects were observed in the animals during the 
first week of the assay apart from the symptoms characteristic of a malaria infection. Except for D. anchorata 
glycan and L. grisea fucan, all compounds reduced parasitemia when compared to untreated controls (Table 3). I. 
badionotus fucan provided the best improvement in mice survival (Fig. 6b), and in one animal treated with this 
compound parasitemia was reduced from 10.4% at day 4 to undetectable levels. Western blot analysis revealed 
the presence of antibodies against P. yoelii antigens in the plasma of surviving mice (Fig. 6c). To explore if the 
observed increased antibody titers were consequence of an immune response against the parasite, the surviving 
animals were re-inoculated with P. yoelii 73 days after the initial infection; all mice, including that treated with 
the I. badionotus fucan, survived the new infection without any treatment (Fig. 6b). Microscopic observation of 
blood smears confirmed the infection of the latter animal, which at day 4 had 18.3% parasitemia (Fig. 6d), and the 
progressive reduction of parasitemia until its complete elimination (Fig. 6e). All surviving animals were alive and 
without symptoms of disease at day 42 after the second, untreated infection.
Discussion
Previous work had demonstrated that the presence of sulfate groups was paramount for the binding of L. grisea 
FucCS to human lung endothelial cells and placenta cryosections under static and flow conditions14, and that 
sulfated FucCS was capable of inhibiting pRBC cytoadherence in these cell models. Because pRBC sequestration 
in the microvasculature of vital organs plays a key role in the pathogenesis of cerebral and pregnancy malaria, L. 
grisea FucCS has been proposed for the treatment of severe disease. The crucial role of sulfate groups in the con-
text of malaria was further evidenced by the ability of L. grisea FucCS to disrupt P. falciparum rosettes, which was 
significantly lost upon desulfation14. Other evidences illustrating the physiological importance of sulfate groups 
came from reports showing that their removal abolished the antithrombotic and anticoagulant effects of FucCS33, 
and that their presence was essential for preserving the inhibitory effects of the polysaccharide in interactions 
mediated by P- and L-selectin41. The in vitro data reported here show that polysaccharides containing α -fucose 
as internal units are less active as antimalarials than polymers having α -fucose as branches. The sulfated fucan 
from I. badionotus was found to have a slightly higher in vitro antimalarial activity than that of L. grisea, probably 
because of the additional 2-sulfation. The observation that both FucCSs have similar in vitro antimalarial effect 
despite the marked differences in their α -fucose-containing branches suggests that, beyond a minimal threshold, 
the presence of additional 2,4-disulfated fucose units does not result in higher antiplasmodial potency, as it was 
similarly reported for the anticoagulant activity of FucCS35.
Figure 2. Alcian Blue-stained polyacrylamide gel electrophoresis analysis of sulfated polysaccharides. 
Approximate molecular masses were confirmed by size exclusion chromatography. CSA: chondroitin sulfate A.
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Compared to heparin, marine sulfated polysaccharides exert their antimalarial activity in vitro at concentra-
tions where their anticoagulant activity is low. The semi-synthetic heparin-like polysaccharide K5-NSOS-H also 
showed high antiplasmodial activity despite of its low anticoagulant capacity16, related to its lack of iduronic acid 
units which are essential to promote the interactions with antithrombin and heparin co-factor II42. However, to 
trace a parallel between the antimalarial and anticoagulant activities of heparin-like molecules and fucosylated 
chondroitin sulfates and sulfated galactan is difficult because these polysaccharides from marine organisms pres-
ent serpin-independent anticoagulant properties31,32. The polysaccharides used in this work do not require frac-
tionation and/or chemical modification after purification31 and, unlike heparin, are not derived from mammals, 
thus reducing the risk of contamination by human-affecting pathogens. These compounds are present at high 
concentrations in marine organisms and can be isolated with relatively high yields of at least ~1% dry weight. The 
synthesis of sulfated polysaccharides from the marine organisms used here is unfeasible because the enzymatic 
Figure 3. In vitro analysis of antimalarial and anticoagulating activities of sulfated polysaccharides. 
(a) Growth inhibition assays of P. falciparum cultures. (b) Activated partial thromboplastin time assay of 
anticoagulant activities, expressed as the ratio between clotting times in the presence (T1) and absence (T0) 
of polysaccharides. Percentages represent the respective anticlotting activities relative to that of heparin. CSA 
is used as a negative control for its lack of anticoagulating activity. The results are shown as the means of three 
independent experiments; the error bars represent standard deviations.
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machinery for their synthesis is still unknown. However, sea cucumbers are already mass cultivated in several 
countries, especially in China, where they are used as food43. Several species of seaweeds are also commercially 
farmed44, and particularly the alga B. occidentalis is abundant in the northeastern coast of Brazil; almost 50% of 
its dry weight is sulfated galactan45, making its harvesting a feasible strategy.
Other already described antimalarial compounds like pentosan polysulfate, curdlan sulfate and dextran sulfate 
are obtained via chemical sulfation of neutral polysaccharides and show serious side effects such as thrombocy-
topenia, intracerebral hemorrhage and colitis46,47. Curdlan sulfate, which has been proposed as adjunct medica-
tion to conventional therapy in patients with severe malaria, has been described to possess as adverse effect an 
increase in APTT48. Fucoidan, also reported to have an inhibitory effect on Plasmodium growth49, had a certain 
level of toxicity for a murine macrophage cell line and was described to occasionally cause eye hemorrhages 
and death of the animals49. Although at concentrations close to their in vitro IC50s marine sulfated polysaccha-
rides exhibited significant toxicity in endothelial cell cultures, higher in vivo amounts did not trigger observable 
adverse effects in mice during the first week of treatment. Consistently, FucCS can be satisfactorily administered 
orally50, without toxic or cumulative effects in tissue observed after daily doses to animals of 50 mg/kg for 30 days 
(Mourão, unpublished data). Nevertheless, the potential unspecific toxicity of sulfated polysaccharides in future 
antimalarial clinical applications can possibly be averted by encapsulating them in pRBC-targeted nanocapsules 
as it has been reported for other antimalarial agents51–53. In the case of heparin, the polysaccharide itself has been 
demonstrated to be capable of acting as targeting molecule of drug-loaded nanocarriers39, thus adding to its own 
antiparasitic action and potentiating therapeutic activity. Some of the pernicious effects of sulfated polysaccha-
rides, such as the anticoagulant activity of heparin, are significantly reduced when immobilized on a substrate54. 
Surface plasmon resonance biosensor studies showed that covalent binding through its carboxyl groups dra-
matically reduced the interaction of heparin with antithrombin III55. Conjugation to nanoparticles can thus be 
explored as an interesting approach to reduce potential toxic side-effects.
We have observed that formation of ring-stage parasites is clearly reduced in the presence of sulfated poly-
saccharides, in agreement with preexisting data indicating that their antimalarial activity unfolds by inhibition 
of merozoite invasion8,9,13–16,49,56–58. The mechanism through which this invasion blocking proceeds has not been 
elucidated yet, although the finding that sulfation patterns are crucial for the inhibitory effect of heparin and 
similar compounds16, suggests that it is the result not only of nonspecific ionic interactions but also of particular 
conformations of anions present in the polysaccharides8. Whereas binding of heparin to merozoites has been 
described to be mediated by multiple protein receptors17,18, GAG-pRBC associations are mainly based on inter-
actions with the parasite-derived adhesin, P. falciparum erythrocyte membrane protein 1, PfEMP159. The subse-
quent internalization of heparin into pRBCs might be an unspecific uptake through the tubulovesicular network 
induced by Plasmodium during its intraerythrocytic growth60. Such entry into pRBCs and coating of developing 
merozoites before they egress, permits the invasion inhibition activity of heparin to be manifested since the first 
moment when Plasmodium cells are free in the blood circulation. This is important regarding possible future ther-
apeutic applications of sulfated polysaccharides; if the observed activity were only exerted upon binding to free, 
extraerythrocytic merozoites, their rapid invasion of RBCs61 would severely compromise clinical applications. 
Because heparin is capable of penetrating live pRBCs and of binding intracellular merozoites39, heparin-based 
antimalarial therapies can be administered during the wide time frame when late stages are present in clinical 
malaria. Smaller fragments of marine polysaccharides might also have this behavior, although the finding that the 
~700 kDa B. occidentalis galactan has antimalarial activity similar to that of the ~30–40 kDa FucCSs from L. grisea 
and I. badionotus suggests that pRBC internalization of the polymers might not be essential for their capacity to 
inhibit Plasmodium growth.
Experimental evidence presented here and elsewhere7–16 has shown that pRBCs and merozoites are targeted by 
different sulfated polysaccharides, and that heparin targets pRBCs and merozoites from widely diverging malarias 
(e.g. human-infecting P. falciparum and the murine malaria parasite P. yoelii39). The widespread pathogen resist-
ance against virtually all currently used drugs6 and the difficulties in selecting heparin-resistant parasites16, places 
antimalarial sulfated polysaccharides as interesting candidate molecules deserving careful exploration.
Methods
Ethics statement. All experiments were performed in accordance with the corresponding relevant guide-
lines and regulations. The studies reported here were performed under protocols reviewed and approved by the 
Ethical Committee on Clinical Research from the Hospital Clínic de Barcelona (Reg. HCB/2014/0910) and the 
Ethical Committee on Animal Experimentation from the Barcelona Science Park (Reg. 20140917). The animal 
Polysaccharide IC50 (μg/mL) IC90 (μg/mL)
Heparin 4.1 8.0
FucCS L. grisea 2.3 5.5
Galactan B. occidentalis 3.5 6.8
FucCS I. badionotus 4.2 7.7
Fucan I. badionotus 9.5 24.8
Fucan L. grisea 20.3 48.8
Glycan D. anchorata 66.3 152.0
CSA >1000 >1000
Table 1. IC50 and IC90 values derived from growth inhibition assays of P. falciparum cultures.
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Figure 4. Microscopic images of Giemsa-stained in vitro pRBC cultures of P. falciparum treated with 
sulfated polysaccharides in an invasion inhibition assay. Pictures corresponding to the cycle phases when 
rings and trophozoites+ schizonts are the dominant forms expected were taken, respectively, 20 and 40 h after 
treatment. Arrows and arrowheads indicate examples, respectively, of ring stages and of merozoites that have 
failed to invade pRBCs.
www.nature.com/scientificreports/
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care and use protocols followed adhered to the specific national and international guidelines specified in the 
Spanish Royal Decree 53/2013, which is based on the European regulation 2010/63/UE. All human blood samples 
used for P. falciparum in vitro cultures were purchased from the Banc de Sang i Teixits (http://www.bancsang.net/) 
and irreversibly anonymized prior to their arrival.
Materials. Except where otherwise indicated, reactions were performed at room temperature (20 °C), and 
reagents were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).
Extraction and purification of sulfated polysaccharides. Samples of the marine organisms were cut 
into 1 mm3 pieces, immersed three times in acetone and dried at 60 °C. Sulfated polysaccharides were extracted 
from 10 g of the desiccated tissues by extensive papain digestion, and the extracts were partially purified by 
cetylpyridinium and ethanol precipitations as described62. Approximately 100 mg dry weight of crude polysac-
charide extract was obtained from each species. Extracts were applied to a high-performance liquid chromatog-
raphy system-linked Mono Q column (GE Healthcare, UK), equilibrated with 5 mM ethylenediaminetetraacetic 
acid, 20 mM Tris-HCl, pH 7.0. The polysaccharides were eluted from the column using a 0–3 M NaCl linear 
gradient at a flow rate of 1 mL/min. 0.5 mL fractions were collected and checked by metachromatic assay using 
1,9-dimethylmethylene blue63, and by measuring conductivity to estimate NaCl concentration. The fractions 
containing sulfated polysaccharides were pooled, dialyzed against distilled water and lyophilized, and the corre-
sponding structures confirmed by nuclear magnetic resonance analysis as described35,37,38.
P. falciparum cell culture and growth inhibition assays. The P. falciparum 3D7 strain was grown in 
vitro in group B human RBCs using previously described conditions51. Briefly, parasites (thawed from glycerol 
stocks) were cultured at 37 °C in Petri dishes containing RBCs in Roswell Park Memorial Institute (RPMI) com-
plete medium under a gas mixture of 92% N2, 5% CO2, and 3% O2. Synchronized cultures were obtained by 
5% sorbitol lysis, and the medium was changed every 2 days keeping 3% hematocrit. For culture maintenance, 
parasitemias were kept below 5% late forms by dilution with washed RBCs prepared as described elsewhere51. 
For growth inhibition assays, parasitemia was adjusted to 1.5% with more than 90% of parasites at ring stage 
after sorbitol synchronization. 150 μL of this Plasmodium culture was plated in 96-well plates and incubated in 
the presence of polysaccharides for 48 h in the conditions described above. Parasitemia was determined by flow 
cytometry, after staining pRBC DNA with the nucleic acid dye Syto 11, added 10 min before analysis. Samples 
were analyzed using a BD FACSCalibur™ flow cytometer and parasitemia was expressed as the number of par-
asitized cells per 100 erythrocytes. Acquisition was configured to stop after recording 50,000 events within the 
RBC population. IC50 and IC90 were derived from non-linear fit dose response curves (Log doses versus nor-
malized inhibitions).
Merozoite invasion inhibition assay. Synchronized cultures of P. falciparum 3D7 were enriched using 
Percoll (GE Healthcare) purification to obtain late trophozoites and early schizonts, and diluted to ~1% initial 
parasitemia and 3% hematocrit. Assays were performed in 24-well, flat-bottomed microculture plates where 1 mL 
of culture was incubated in RPMI supplemented with different amounts of each polysaccharide in study, for 20 h 
as described above. After incubation, smears were prepared by fixing cells in methanol for a few seconds and then 
staining them for 10 min with Giemsa (Merck Chemicals, Germany) diluted 1:10 in Sorenson’s Buffer, pH 7.2. 
Plates were incubated for another 20 h before preparing a new set of smears. Slides were observed with an optical 
microscope Nikon Eclipse 50i (Japan) and pictures were taken with a Nikon Digital Sight DS-U2 camera. For 
quantitative determinations, the cultures were analyzed by flow cytometry as described above. To assess invasion 
and maturation rates, respectively, the following formulae were applied:
=
+ −
Invasion
rings
(trophozoites schizonts) (1)n
day n
day 1
Compound Invasion rate Maturation rate
Not treated 3.60 ± 0.10 0.96 ± 0.06
FucCS L. grisea 0.32 ± 0.02*** 2.73 ± 0.09**
Galactan B. occidentalis 1.10 ± 0.10*** 1.14 ± 0.08
FucCS I. badionotus 1.00 ± 0.19** 1.50 ± 0.20
Fucan I. badionotus 2.61 ± 0.04** 1.05 ± 0.05
Fucan L. grisea 1.74 ± 0.38* 1.75 ± 0.09**
Glycan D. anchorata 1.93 ± 0.55* 1.19 ± 0.34
Table 2. Invasion and maturation rates corresponding to the invasion inhibition assay from Fig. 4. 
The data are derived from microscopic counting at, respectively, 20 and 40 h post-treatment of the samples 
incubated with 4 μg/mL of sulfated polysaccharides. The results are shown as the means of three independent 
experiments ± standard deviation, with 900 cells counted for each sample (300 × 3 replicates). Significant 
differences relative to non-treated control as determined by t-tests are indicated by asterisks (*p< 0.05, 
**p< 0.005, ***p< 0.001).
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=
+
−
Maturation
(trophozoites schizonts)
rings (2)n
day n
day 1
Activated partial thromboplastin time (APTT) assay. Various concentrations of sulfated polysaccha-
rides in 100 μL of human plasma were mixed with 100 μL of undiluted APTT reagent (kaolin bovine phospho-
lipid reagent from Biolab-Merieux AS, Rio de Janeiro, Brazil). After incubating for 2 min at 37 °C, 100 μL of 
25 mM CaCl2 was added to the mixture, and the clotting time was recorded in an Amelung KC4A coagulometer 
(Heinrich Amelung GmbH, Lemgo, Germany). The results were expressed as the clotting time ratio in the pres-
ence vs. absence of different polysaccharide concentrations. Anticoagulant activity was indicated as IU/mg using 
a parallel standard curve based on the 6th International Heparin Standard (2,145 units per vial, 200.04 IU/mg), 
obtained from the National Institute for Biological Standards and Control (Potters Bar, UK).
Fluorescence microscopy. Living P. falciparum cultures with mature stages of the parasite were incubated 
in the presence of 10 μg/mL fluorescein-labeled heparin (Life Technologies) in phosphate buffered saline, pH 7.4 
Figure 5. Flow cytometry analysis of the inhibition of red blood cell invasion by P. falciparum in 
the presence of sulfated polysaccharides. The values indicate the corresponding absolute percentages 
(parasitemias) of rings and schizonts in the cultures, 20 h after treatment and at polysaccharide concentrations 
corresponding to the respective (a) IC50 and (b) IC90 reported in Table 1. The results are shown as the means 
of three independent experiments; the error bars represent standard deviations. Significant differences in the 
numbers of rings and schizonts relative to the respective non-treated controls as determined by t-tests are 
indicated by asterisks (*p< 0.05, **p< 0.005, ***p< 0.001).
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Figure 6. Cytotoxicity and in vivo antimalarial activity analyses of sulfated polysaccharides. (a) Unspecific 
toxicity for human umbilical vein endothelial cell cultures of sulfated polysaccharides assayed at concentrations 
around their respective IC50 for P. falciparum growth in vitro. The results are shown as the means of three 
independent experiments; the error bars represent standard deviations. (b) Kaplan-Meier plot for the in vivo 
assay of the effect on P. yoelii-infected mice (n = 5 animals/sample) of polysaccharides administered iv at 
the estimated μg mL−1 day−1 indicated in Table 3. Chloroquine was administered iv as a positive control at 
a dose of 5 mg kg−1 day−1. (c) Western blot for the detection of IgGs against P. yoelii antigens in the serum of 
surviving infected mice that had been treated 35 days before with chloroquine or with the I. badionotus fucan. 
The untreated control corresponds to a noninfected mouse of the same age. (d,e) Microscope images of blood 
samples from the surviving I. badionotus fucan-treated mouse at (d) day 4 and (e) day 40 after reinfection 
without further treatment.
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(PBS) supplemented with 0.75% bovine serum albumin, for 30 min at 37 °C with gentle stirring. After PBS wash-
ing, blood smears were prepared and cells were fixed for 20 min with 1% (v/v) paraformaldehyde in PBS. Parasite 
nuclei were stained with 4′ 6-diamino-2-phenylindole (DAPI) and the RBC membrane was labeled with wheat 
germ agglutinin–tetramethylrhodamine conjugate. Slides were finally mounted with ProLong® Gold antifade 
reagent, and analyzed with a Leica TCS SP5 laser scanning confocal microscope.
Polyacrylamide gel electrophoresis. Electrophoresis was performed in 6% polyacrylamide gels using a 
Mini-Protean Tetra Cell System (Bio-Rad Laboratories Inc.). Samples containing 20 μg polysaccharide (at 1 mg/
mL) were boiled in the presence of nonreducing sample buffer for 5 min, and electrophoresed at 100 V for 40 min. 
The gel was stained with 0.5% Alcian Blue solution in 3% acetic acid/25% isopropanol for 30 min with gentle stir-
ring. Finally, the gel was de-stained in 10% acetic acid/40% ethanol overnight and digitalized.
Unspecific cytotoxicity assay. Human umbilical vein endothelial cells (primary culture provided by 
Dr. Francisco J. Muñoz, Pompeu Fabra University, Barcelona, Spain) were seeded in 96-well plates at a density 
of 5000 cells/100 μL/well, and incubated for 24 h at 37 °C in Medium 199 with Earle’s salts, supplemented with 
L-glutamine and fetal calf serum (FCS; LabClinics). After that time the medium was carefully removed with a 
pipette, and 100 μL of new medium (without FCS in this case) containing different sample concentrations was 
added. After incubating for 48 h at 37 °C, 10 μL of the cell proliferation assay reagent WST-1 (Roche Life Science) 
was added, and 1 h later absorbance was measured at 440 nm.
Antimalarial activity assay in vivo. The in vivo antimalarial activity of sulfated polysaccharides was stud-
ied in a 4-day blood suppressive test as previously described64. Briefly, Balb/C female mice (n = 5/sample; Janvier 
Laboratories) were inoculated intraperitoneally with 2 × 106 RBCs extracted from an animal infected by the 
Plasmodium yoelii yoelii 17 XL lethal strain. Treatment with the antimalarial drug chloroquine (5 mg kg−1 day−1)65 
or polysaccharides dissolved in PBS started 2 h later (day 0) with a 200-μL single dose administered intravenously, 
followed by identical dose administration for the next 3 days. To obtain the desired final in vivo doses, the com-
pounds were prepared 10× concentrated, assuming a volume of 2 mL of circulating mouse blood. A control 
untreated group received PBS. Activity was determined by microscopic counting at day 4 of blood smears stained 
with Wright’s solution (Merck Chemicals). Mice were fed a commercial diet ad libitum and treated with humane 
care, being euthanized if reaching a 20% weight loss for two consecutive days. The sacrifice method was exposure 
to 95% CO2 following anesthesia with 5% isoflurane vaporized in O2. On day 73 after the initial inoculation those 
surviving animals were re-inoculated as described above. The mice did not receive any treatment after this second 
infection and parasitemia was monitored by blood smear counting.
P. yoelii protein extraction from infected whole blood. Protein lysates were extracted from the whole 
blood of infected Balb/C female mice having >50% parasitemia. Blood was collected in Microvette® CB 300 
tubes (Sarstedt, Germany) and kept at −80 °C until protein extraction. RBC lysis was performed by adding 10× 
vol of saponin 0.1% (w/v) in PBS. After washing twice with cold PBS, the pellet was treated with 2 vol of extrac-
tion buffer consisting of 50 mM NaCl, 0.5% Mega 10, 3% CHAPS, and 50 mM Tris-HCl, pH 8.0, supplemented 
with a protease inhibitor cocktail (Roche). The samples were subjected to four freeze-thaw cycles, and the lysates 
were finally centrifuged at 20,000 g for 30 min (4 °C). Protein concentration was determined by the DC protein 
assay (Bio-Rad), and P. yoelii total protein samples were stored at −20 °C until use.
Western blot. 10 μg of P. yoelii total protein extract were fractionated in a reducing 10% SDS-PAGE 
(Bio-Rad), transferred to polyvinylidene difluoride membranes and blocked with Z buffer (100 mM MgCl2, 
0.5% Tween 20, 1% Triton X-100, 1% BSA,100 mM Tris-HCl, pH 7.4, supplemented with 5% FCS). Membranes 
were then incubated at 4 °C overnight with 1:10,000 dilutions of sera from the mice that survived the infec-
tion, followed by a 1-h incubation with secondary horseradish peroxidase-labeled anti-mouse IgG (Amersham 
Biosciences) at a 1:10,000 dilution.
Treatment μg compound mL−1 day−1 Day 4 parasitemia
Not treated – 19.9 ± 9.3
Chloroquine 5.0 1.4 ± 0.2
Galactan B. occidentalis 5.6 18.4 ± 1.3
FucCS I. badionotus 8.0 14.0 ± 1.1
FucCS L. grisea 10.0 11.0 ± 5.2
Fucan L. grisea 11.0 22.3 ± 5.5
Fucan I. badionotus 15.0 14.3 ± 5.6
Glycan D. anchorata 125.0 21.6 ± 2.8
Table 3. Estimated compound concentrations in blood and determined day 4 parasitemias for the in vivo 
assay from Fig. 6b. These daily administered doses assume 2 mL of blood in a mouse into which were injected 
200 μL of 10× concentrated compound solutions. The results are shown as the means of five independent 
experiments ± standard deviation.
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Statistical analysis. Data are presented as the mean ± standard deviation of at least three independent 
experiments, and the corresponding standard deviations in histograms are represented by error bars. Cell counts 
from Giemsa-stained slides were done using the Plasmoscore programme. The parametric Student’s t-test was 
used to compare two independent groups when data followed a Gaussian distribution, and differences were con-
sidered significant when p ≤ 0.05. Percentages of viability were obtained using non-treated cells as control of 
survival and IC50 values were calculated by nonlinear regression with an inhibitory dose-response model using 
GraphPad Prism5 software (95% confidence interval). Concentrations were transformed using natural log for 
linear regression. Regression models were adjusted for replicates and assay data. In anticoagulant assays, the 
polysaccharide concentrations (mean ± standard deviation) necessary to double the control (T0) APTT66 were 
compared via one-way ANOVA with Tukey´s test using the software Origin-Pro 8.0 (OriginLab).
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